In a patient with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency who has Ebola virus disease, how should the infection be treated and what medication adjustments are required?

G6PD deficiency and Ebola virus disease: treatment and medication choices

Avoid oxidant drugs that trigger hemolysis (primaquine, tafenoquine, dapsone, rasburicase, methylene blue) and treat Ebola with aggressive supportive care in a certified treatment unit; no G6PD-specific antiviral adjustments are required because no proven Ebola antivirals exist. 1, 2, 3, 4

Algorithm (prioritizing mortality, morbidity, and quality of life)

• Immediate setting and infection control

  • Manage in an Ebola-designated center with strict PPE and protocols to protect staff and ensure full supportive care capability (best survival impact) 2.
  • For children, balance caregiver presence with infection-control capacity per pediatric guidance; use remote presence if bedside cannot be safely supported 5.

• Core Ebola treatment (no proven antiviral; survival hinges on organ support)

  • Fluids and electrolytes: Replace large GI losses; target euvolemia; correct Na, K, Ca, Mg; frequent labs and point-of-care monitoring 2.
  • Shock: Early IV crystalloids; vasopressors if hypotension persists 2.
  • AKI: Early renal replacement therapy if indicated 2.
  • Respiratory failure: Intubation/ventilation as needed, with strict infection control 2.
  • Co-infections: Culture/rapid tests; start empiric antibiotics if bacterial sepsis suspected; de-escalate as data return 2.
  • Hemostasis: Monitor for DIC; transfuse blood components per labs/bleeding 2.
  • Nutrition, pain/anxiety control, and psychosocial support 2.
  • Rationale/strength: Most recent high-quality clinical guidance emphasizes intensive supportive care as the main determinant of survival in Ebola; no proven antiviral therapy to date 2, 1.

• G6PD-specific medication adjustments and lab monitoring (to prevent hemolysis and methemoglobinemia)

  • Absolutely avoid high-risk oxidant drugs:
    • Primaquine, tafenoquine, dapsone, rasburicase, methylene blue, nitrofurantoin, phenazopyridine, toluidine blue 3, 4.
  • Caution:
    • If methemoglobinemia occurs, do not give methylene blue; consider alternatives (e.g., oxygen, exchange transfusion; cautious low-dose ascorbic acid if benefit > risk and hemolysis is controlled) 4, 6.
  • Antipyretics/analgesia:
    • Acetaminophen is generally acceptable; avoid NSAIDs during active hemorrhagic risk and because intercurrent infection/NSAIDs can exacerbate hemolysis in G6PD deficiency 7.
  • Uric acid management:
    • Do not use rasburicase; if hyperuricemia must be treated, prefer allopurinol (monitor) 4.
  • Antimalarials (only if malaria coinfection is confirmed/suspected):
    • Do not use primaquine/tafenoquine for radical cure in G6PD deficiency; if absolutely necessary for P. vivax/ovale hypnozoites, use specialized weekly primaquine regimens only when G6PD activity permits and with close hemolysis monitoring; otherwise omit radical cure acutely and plan post-crisis management 8.
    • Artemisinin-based therapies (e.g., artesunate for severe malaria) are acceptable; monitor for hemolysis (PADH) after artesunate 8.
  • Hemolysis surveillance:
    • Daily CBC, bilirubin, LDH, haptoglobin, creatinine; urine color; prompt transfusion support if Hb drops or symptomatic anemia develops 4.
  • Note infection itself can precipitate hemolysis in G6PD deficiency; anticipate and monitor accordingly 4.

• Pitfalls to avoid

  • Starting rasburicase for hyperuricemia or tumor lysis–like states in G6PD deficiency (can cause catastrophic hemolysis/methemoglobinemia) 3, 4.
  • Treating methemoglobinemia with methylene blue in G6PD deficiency (ineffective and worsens hemolysis) 4, 6.
  • Using primaquine/tafenoquine empirically in febrile illness in endemic areas without quantitative G6PD testing 8, 3.

• Nuances and evidence notes

  • Most recent, highest-quality Ebola management emphasizes that intensive supportive care reduces mortality; no definitive antiviral benefit proven to date 2, 1.
  • Drug safety in G6PD deficiency: strong evidence of harm for a short list of oxidant drugs; many other agents are likely safe at therapeutic doses, but infection itself raises hemolysis risk—monitor closely 3, 4.
  • Some G6PD variants carry higher hemolysis risk; if known severe variants or very low activity, be extra conservative with any oxidant stressors 8, 4.
  • Severe G6PD deficiency can impair ROS-dependent immune function, potentially increasing infection risks; underscores the need for vigilant infection surveillance and prompt treatment 9, 10.

One-page orders (practical)

• Location: Ebola treatment unit with ICU capability; strict PPE; closed-loop med administration 2.
• Lines/monitoring: Central access if needed; frequent vitals; continuous cardiac monitoring if vasopressors; strict I/O 2.
• Labs q6–12h initially: BMP, Mg, Ca, CBC with diff, LFTs, coagulation, lactate; hemolysis panel daily; type & screen 2, 4.
• Fluids: Balanced crystalloids; titrate to perfusion goals; electrolyte repletion per labs 2.
• Vasopressors: Norepinephrine first-line if shock persists 2.
• AKI: Early CRRT if indicated 2.
• Antimicrobials: Start if sepsis suspected; adjust to cultures 2.
• Pain/fever: Acetaminophen; avoid NSAIDs; avoid aspirin 7.
• Absolutely avoid: Primaquine, tafenoquine, dapsone, rasburicase, methylene blue, nitrofurantoin, phenazopyridine, toluidine blue 3, 4.
• If malaria coinfection severe: IV artesunate; monitor for delayed hemolysis (PADH) days 1–3 weeks post-therapy 8.
• Transfuse: PRBCs for symptomatic anemia or Hb drop; platelets/FFP/cryoprecipitate per bleeding/coagulation profile 2.
• Methemoglobinemia (if present): High-flow oxygen; avoid methylene blue; consider exchange transfusion if severe and unstable 6, 4.